How much did Cosmo Pharmaceuticals achieve in EBIT for the current year?
In the current year, Cosmo Pharmaceuticals has achieved an EBIT of 165.57 M EUR.
Cosmo Pharmaceuticals EBIT 2024
Cosmo Pharmaceuticals EBIT
165.57 M EUR
Ticker
COPN.SW
ISIN
NL0011832936
WKN
A2AJ68
In 2024, Cosmo Pharmaceuticals's EBIT was 165.57 M EUR, a 1,254.25% increase from the 12.23 M EUR EBIT recorded in the previous year.
The Cosmo Pharmaceuticals EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2029e | - |
| 2028e | 110.83 |
| 2027e | 106.44 |
| 2026e | 107.54 |
| 2025e | 125.97 |
| 2024e | 165.57 |
| 2023 | 12.23 |
| 2022 | 28.06 |
| 2021 | 11.1 |
| 2020 | 2.91 |
| 2019 | -12.31 |
| 2018 | -16.62 |
| 2017 | -9.6 |
| 2016 | 24.63 |
| 2015 | -5.43 |
| 2014 | 22.21 |
| 2013 | 12.94 |
| 2012 | 26.46 |
| 2011 | 8.91 |
| 2010 | 4.8 |
| 2009 | 4.44 |
| 2008 | 11.18 |
| 2007 | -0.25 |
| 2006 | 1.44 |
Cosmo Pharmaceuticals Revenue, EBIT, Net Income NL0011832936 · A2AJ68
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Cosmo Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cosmo Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cosmo Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Cosmo Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Cosmo Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Cosmo Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cosmo Pharmaceuticals’s growth potential.
Cosmo Pharmaceuticals Revenue, EBIT and net profit per share
| Date | Cosmo Pharmaceuticals Revenue | Cosmo Pharmaceuticals EBIT | Cosmo Pharmaceuticals Net Income |
|---|---|---|---|
| 2029e | 556.57 M undefined | 0 undefined | 271.43 M undefined |
| 2028e | 248.71 M undefined | 110.83 M undefined | 83.19 M undefined |
| 2027e | 235.95 M undefined | 106.44 M undefined | 79.42 M undefined |
| 2026e | 256.7 M undefined | 107.54 M undefined | 78.94 M undefined |
| 2025e | 252.27 M undefined | 125.97 M undefined | 91.04 M undefined |
| 2024e | 269.85 M undefined | 165.57 M undefined | 123.69 M undefined |
| 2023 | 96.72 M undefined | 12.23 M undefined | 1.15 M undefined |
| 2022 | 102.09 M undefined | 28.06 M undefined | 17.23 M undefined |
| 2021 | 65.07 M undefined | 11.1 M undefined | 21.67 M undefined |
| 2020 | 60.95 M undefined | 2.91 M undefined | -7.9 M undefined |
| 2019 | 62.5 M undefined | -12.31 M undefined | -24.42 M undefined |
| 2018 | 65.62 M undefined | -16.62 M undefined | -18.01 M undefined |
| 2017 | 67.24 M undefined | -9.6 M undefined | -32.45 M undefined |
| 2016 | 67.66 M undefined | 24.63 M undefined | 19.34 M undefined |
| 2015 | 60.61 M undefined | -5.43 M undefined | 248.19 M undefined |
| 2014 | 79.59 M undefined | 22.21 M undefined | 73.32 M undefined |
| 2013 | 56.37 M undefined | 12.94 M undefined | 68.73 M undefined |
| 2012 | 59.54 M undefined | 26.46 M undefined | 19.32 M undefined |
| 2011 | 33.51 M undefined | 8.91 M undefined | 7.6 M undefined |
| 2010 | 32.05 M undefined | 4.8 M undefined | 3.61 M undefined |
| 2009 | 26.69 M undefined | 4.44 M undefined | 4.05 M undefined |
| 2008 | 34.17 M undefined | 11.18 M undefined | 9.4 M undefined |
| 2007 | 22.42 M undefined | -250,000 undefined | 120,000 undefined |
| 2006 | 20.09 M undefined | 1.44 M undefined | -340,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2006 | 20.09 M EUR | 1.44 M EUR | -340,000 EUR |
| 2007 | 22.42 M EUR | -250,000 EUR | 120,000 EUR |
| 2008 | 34.17 M EUR | 11.18 M EUR | 9.4 M EUR |
| 2009 | 26.69 M EUR | 4.44 M EUR | 4.05 M EUR |
| 2010 | 32.05 M EUR | 4.8 M EUR | 3.61 M EUR |
| 2011 | 33.51 M EUR | 8.91 M EUR | 7.6 M EUR |
| 2012 | 59.54 M EUR | 26.46 M EUR | 19.32 M EUR |
| 2013 | 56.37 M EUR | 12.94 M EUR | 68.73 M EUR |
| 2014 | 79.59 M EUR | 22.21 M EUR | 73.32 M EUR |
| 2015 | 60.61 M EUR | -5.43 M EUR | 248.19 M EUR |
| 2016 | 67.66 M EUR | 24.63 M EUR | 19.34 M EUR |
| 2017 | 67.24 M EUR | -9.6 M EUR | -32.45 M EUR |
| 2018 | 65.62 M EUR | -16.62 M EUR | -18.01 M EUR |
| 2019 | 62.5 M EUR | -12.31 M EUR | -24.42 M EUR |
| 2020 | 60.95 M EUR | 2.91 M EUR | -7.9 M EUR |
| 2021 | 65.07 M EUR | 11.1 M EUR | 21.67 M EUR |
| 2022 | 102.09 M EUR | 28.06 M EUR | 17.23 M EUR |
| 2023 | 96.72 M EUR | 12.23 M EUR | 1.15 M EUR |
| 2024e | 269.85 M EUR | 165.57 M EUR | 123.69 M EUR |
| 2025e | 252.27 M EUR | 125.97 M EUR | 91.04 M EUR |
| 2026e | 256.7 M EUR | 107.54 M EUR | 78.94 M EUR |
| 2027e | 235.95 M EUR | 106.44 M EUR | 79.42 M EUR |
| 2028e | 248.71 M EUR | 110.83 M EUR | 83.19 M EUR |
| 2029e | 556.57 M EUR | 0 EUR | 271.43 M EUR |
Cosmo Pharmaceuticals stock margins NL0011832936 · A2AJ68
The Cosmo Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cosmo Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cosmo Pharmaceuticals.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Cosmo Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Cosmo Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Cosmo Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Cosmo Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cosmo Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cosmo Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cosmo Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Cosmo Pharmaceuticals Margin History
| Cosmo Pharmaceuticals Gross margin | Cosmo Pharmaceuticals Profit margin | Cosmo Pharmaceuticals EBIT margin | Cosmo Pharmaceuticals Profit margin |
|---|---|---|---|
| 2029e | 59.33 % | 0 % | 48.77 % |
| 2028e | 59.33 % | 44.56 % | 33.45 % |
| 2027e | 59.33 % | 45.11 % | 33.66 % |
| 2026e | 59.33 % | 41.89 % | 30.75 % |
| 2025e | 59.33 % | 49.93 % | 36.09 % |
| 2024e | 59.33 % | 61.36 % | 45.84 % |
| 2023 | 59.33 % | 12.64 % | 1.19 % |
| 2022 | 60.34 % | 27.48 % | 16.87 % |
| 2021 | 49.32 % | 17.06 % | 33.3 % |
| 2020 | 54.69 % | 4.77 % | -12.96 % |
| 2019 | 59.91 % | -19.69 % | -39.07 % |
| 2018 | 66.38 % | -25.33 % | -27.44 % |
| 2017 | 67.3 % | -14.28 % | -48.25 % |
| 2016 | 70.66 % | 36.4 % | 28.58 % |
| 2015 | 66.82 % | -8.97 % | 409.51 % |
| 2014 | 72.94 % | 27.91 % | 92.12 % |
| 2013 | 66.01 % | 22.96 % | 121.93 % |
| 2012 | 72.69 % | 44.44 % | 32.45 % |
| 2011 | 56.76 % | 26.59 % | 22.68 % |
| 2010 | 55.29 % | 14.98 % | 11.26 % |
| 2009 | 52.12 % | 16.64 % | 15.17 % |
| 2008 | 61.37 % | 32.72 % | 27.51 % |
| 2007 | 72.03 % | -1.12 % | 0.54 % |
| 2006 | 72.67 % | 7.17 % | -1.69 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2006 | 72.67 % | 7.17 % | -1.69 % |
| 2007 | 72.03 % | -1.12 % | 0.54 % |
| 2008 | 61.37 % | 32.72 % | 27.51 % |
| 2009 | 52.12 % | 16.64 % | 15.17 % |
| 2010 | 55.29 % | 14.98 % | 11.26 % |
| 2011 | 56.76 % | 26.59 % | 22.68 % |
| 2012 | 72.69 % | 44.44 % | 32.45 % |
| 2013 | 66.01 % | 22.96 % | 121.93 % |
| 2014 | 72.94 % | 27.91 % | 92.12 % |
| 2015 | 66.82 % | -8.97 % | 409.51 % |
| 2016 | 70.66 % | 36.4 % | 28.58 % |
| 2017 | 67.3 % | -14.28 % | -48.25 % |
| 2018 | 66.38 % | -25.33 % | -27.44 % |
| 2019 | 59.91 % | -19.69 % | -39.07 % |
| 2020 | 54.69 % | 4.77 % | -12.96 % |
| 2021 | 49.32 % | 17.06 % | 33.3 % |
| 2022 | 60.34 % | 27.48 % | 16.87 % |
| 2023 | 59.33 % | 12.64 % | 1.19 % |
| 2024e | 59.33 % | 61.36 % | 45.84 % |
| 2025e | 59.33 % | 49.93 % | 36.09 % |
| 2026e | 59.33 % | 41.89 % | 30.75 % |
| 2027e | 59.33 % | 45.11 % | 33.66 % |
| 2028e | 59.33 % | 44.56 % | 33.45 % |
| 2029e | 59.33 % | 0 % | 48.77 % |
Cosmo Pharmaceuticals Aktienanalyse
What does Cosmo Pharmaceuticals do?
Cosmo Pharmaceuticals NV is an international pharmaceutical company based in Dublin, Ireland. The company focuses on developing innovative drugs for various diseases, including gastroenterology, oncology, and infectious diseases. The history of Cosmo Pharmaceuticals dates back to 1997 when it was founded by Dr. Mauro Ajani in Italy. Since then, the company has undergone impressive development and is now listed on the SIX Swiss Exchange. In 2020, the company moved from Italy to Ireland to strengthen its international presence. Cosmo Pharmaceuticals' business model is based on creating patented innovations and technologies in drug development. The company works closely with other companies and research institutions to introduce a wide range of products that benefit both patients and healthcare providers. The main source of income for Cosmo Pharmaceuticals is the licenses they grant for their products, as well as the manufacturing and sale of their own products. Cosmo Pharmaceuticals operates three main business areas: Human, Veterinary, and Proprietary. The Human division specializes in the development of drugs for humans. The company's products are available worldwide, including in the United States, Europe, Japan, and China. In the field of gastroenterology, Cosmo Pharmaceuticals is one of the leading companies on the market and has developed several products to treat gastrointestinal problems and other gastrointestinal diseases. The Veterinary division of Cosmo Pharmaceuticals specializes in the development of animal medicines. The company works with veterinarians and pet owners to bring products to market that help animals stay healthy or recover. Cosmo Pharmaceuticals offers several products tailored to the specific needs of animals, including Ballistol Animal, used for skin and fur care, and Otilonium Bromide, used for digestive disorders in horses. The Proprietary division is the third major business area of Cosmo Pharmaceuticals. This is a segment that manufactures its own products and sells them directly to patients or institutions. The company's products include Eleview, used in endoscopy to improve visibility of the gastrointestinal mucosa. Cosmo Pharmaceuticals is an innovative company focused on the development of drugs that can help improve patients' lives. The company collaborates closely with other companies and research institutions to leverage the latest technologies and developments in the industry. With its broad portfolio of products in the field of gastroenterology, oncology, and infectious diseases, the company has a strong presence in the industry and actively advocates for more people to have access to the best medical treatments. Cosmo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Cosmo Pharmaceuticals's EBIT
Cosmo Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Cosmo Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Cosmo Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Cosmo Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Cosmo Pharmaceuticals stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Cosmo Pharmaceuticals.
How has the EBIT of Cosmo Pharmaceuticals developed in recent years?
The EBIT of Cosmo Pharmaceuticals has increased by 1,254.245% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Cosmo Pharmaceuticals?
The EBIT of Cosmo Pharmaceuticals is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Cosmo Pharmaceuticals pay?
Over the past 12 months, Cosmo Pharmaceuticals paid a dividend of 1.05 EUR . This corresponds to a dividend yield of about 1.29 %. For the coming 12 months, Cosmo Pharmaceuticals is expected to pay a dividend of 1.05 EUR.
What is the dividend yield of Cosmo Pharmaceuticals?
The current dividend yield of Cosmo Pharmaceuticals is 1.29 %.
When does Cosmo Pharmaceuticals pay dividends?
Cosmo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, June, June, August.
How secure is the dividend of Cosmo Pharmaceuticals?
Cosmo Pharmaceuticals paid dividends every year for the past 8 years.
What is the dividend of Cosmo Pharmaceuticals?
For the upcoming 12 months, dividends amounting to 1.05 EUR are expected. This corresponds to a dividend yield of 1.3 %.
In which sector is Cosmo Pharmaceuticals located?
Cosmo Pharmaceuticals is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cosmo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cosmo Pharmaceuticals from 7/12/2024 amounting to 2 EUR, you needed to have the stock in your portfolio before the ex-date on 7/10/2024.
When did Cosmo Pharmaceuticals pay the last dividend?
The last dividend was paid out on 7/12/2024.
What was the dividend of Cosmo Pharmaceuticals in the year 2023?
In the year 2023, Cosmo Pharmaceuticals distributed 0.95 EUR as dividends.
In which currency does Cosmo Pharmaceuticals pay out the dividend?
The dividends of Cosmo Pharmaceuticals are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Cosmo Pharmaceuticals
Our stock analysis for Cosmo Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cosmo Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Cosmo Pharmaceuticals Revenue
- Cosmo Pharmaceuticals Net Income
- Cosmo Pharmaceuticals P/E
- Cosmo Pharmaceuticals P/S
- Cosmo Pharmaceuticals EBIT
- Cosmo Pharmaceuticals Dividend
- Cosmo Pharmaceuticals Stocks
- Cosmo Pharmaceuticals Market capitalization
- Cosmo Pharmaceuticals Debt
- Cosmo Pharmaceuticals Liabilities
- Cosmo Pharmaceuticals Equity
- Cosmo Pharmaceuticals AAQS
- Cosmo Pharmaceuticals Employees
- Cosmo Pharmaceuticals ROE
- Cosmo Pharmaceuticals ROA
- Cosmo Pharmaceuticals ROCE
